Oct 22, 2024 · ABRYSVO now offers the broadest RSV vaccine indication for adults, which previously included those 60 years and older. Additionally, it remains the only RSV immunization approved for pregnant individuals at 32 through 36 weeks of gestation to protect infants from birth up to 6 months of age.

Respiratory syncytial virus, also known as RSV, is a virus that can cause an infection in the lungs and airways, producing symptoms that are often similar to a mild cold.

ABRYSVO is a vaccine indicated for active immunization of pregnant individuals at 32 through 36 weeks gestational age for the prevention of lower respiratory tract disease (LRTD) and severe LRTD caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age.

Oct 30, 2024 · Abrysvo is made by Pfizer and was approved on May 31, 2023; the second RSV vaccine to be approved for older adults. It was FDA-approved for pregnant women on August 21, 2023, and its approval was further extended to include adults aged 18 through 59 years at higher risk of LRTD on October 22, 2024.

Sep 19, 2023 · Abrysvo: Pfizer’s RSV vaccine. Pfizer’s trial of 34,284 participants showed that Abrysvo had an 85.7% efficacy in preventing RSV lower respiratory tract disease with three or more symptoms. It dropped to 66.7% when looking at people with just two or more symptoms.

ABRYSVO (Respiratory Syncytial Virus Vaccine) is a sterile solution for intramuscular injection. The vaccine is supplied as a vial of Lyophilized Antigen Component that is reconstituted at the time of use with a Sterile Water Diluent Component. The antigen component contains recombinant RSV preF A and RSV preF B.

Three RSV vaccines are currently available for adults ages 60 and older: GSK’s Arexvy, Moderna’s mResvia, and Pfizer’s Abrysvo. Eligible older adults may receive any of the licensed RSV vaccines.

Oct 22, 2024 · Abrysvo now offers the broadest RSV vaccine indication for adults, which previously included those 60 years and older. Additionally, it remains the only RSV immunization approved for pregnant individuals at 32 through 36 weeks of gestation to protect infants from birth up to 6 months of age.